Cargando…
Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry
BACKGROUND: COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer r...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436757/ https://www.ncbi.nlm.nih.gov/pubmed/35896207 http://dx.doi.org/10.1183/13993003.00795-2022 |
_version_ | 1785092404266663936 |
---|---|
author | Tisi, Sophie Dickson, Jennifer L. Horst, Carolyn Quaife, Samantha L. Hall, Helen Verghese, Priyam Gyertson, Kylie Bowyer, Vicky Levermore, Claire Mullin, Anne-Marie Teague, Jonathan Farrelly, Laura Nair, Arjun Devaraj, Anand Hackshaw, Allan Hurst, John R. Janes, Sam M. |
author_facet | Tisi, Sophie Dickson, Jennifer L. Horst, Carolyn Quaife, Samantha L. Hall, Helen Verghese, Priyam Gyertson, Kylie Bowyer, Vicky Levermore, Claire Mullin, Anne-Marie Teague, Jonathan Farrelly, Laura Nair, Arjun Devaraj, Anand Hackshaw, Allan Hurst, John R. Janes, Sam M. |
author_sort | Tisi, Sophie |
collection | PubMed |
description | BACKGROUND: COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer risk in COPD. In this study, we wished to understand the prevalence, severity, clinical phenotype and lung cancer risk of individuals with symptomatic undiagnosed COPD in a LCS cohort. METHODS: 16 010 current or former smokers aged 55–77 years attended a lung health check as part of the SUMMIT Study. A respiratory consultation and spirometry were performed alongside LCS eligibility assessment. Those with symptoms, no previous COPD diagnosis and airflow obstruction were labelled as undiagnosed COPD. Baseline low-dose computed tomography (LDCT) was performed in those at high risk of lung cancer (PLCO(m2012) score ≥1.3% and/or meeting USPSTF 2013 criteria). RESULTS: Nearly one in five (19.7%) met criteria for undiagnosed COPD. Compared with those previously diagnosed, those undiagnosed were more likely to be male (59.1% versus 53.2%; p<0.001), currently smoking (54.9% versus 47.6%; p<0.001) and from an ethnic minority group (p<0.001). Undiagnosed COPD was associated with less forced expiratory volume in 1 s impairment (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 and 2: 85.3% versus 68.4%; p<0.001) and lower symptom/exacerbation burden (GOLD A and B groups: 95.6% versus 77.9%; p<0.001) than those with known COPD. Multivariate analysis demonstrated that airflow obstruction was an independent risk factor for lung cancer risk on baseline LDCT (adjusted OR 2.74, 95% CI 1.73–4.34; p<0.001), with a high risk seen in those with undiagnosed COPD (adjusted OR 2.79, 95% CI 1.67–4.64; p<0.001). CONCLUSIONS: Targeted case-finding within LCS detects high rates of undiagnosed symptomatic COPD in those most at risk. Individuals with undiagnosed COPD are at high risk for lung cancer. |
format | Online Article Text |
id | pubmed-10436757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-104367572023-08-19 Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry Tisi, Sophie Dickson, Jennifer L. Horst, Carolyn Quaife, Samantha L. Hall, Helen Verghese, Priyam Gyertson, Kylie Bowyer, Vicky Levermore, Claire Mullin, Anne-Marie Teague, Jonathan Farrelly, Laura Nair, Arjun Devaraj, Anand Hackshaw, Allan Hurst, John R. Janes, Sam M. Eur Respir J Original Research Articles BACKGROUND: COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer risk in COPD. In this study, we wished to understand the prevalence, severity, clinical phenotype and lung cancer risk of individuals with symptomatic undiagnosed COPD in a LCS cohort. METHODS: 16 010 current or former smokers aged 55–77 years attended a lung health check as part of the SUMMIT Study. A respiratory consultation and spirometry were performed alongside LCS eligibility assessment. Those with symptoms, no previous COPD diagnosis and airflow obstruction were labelled as undiagnosed COPD. Baseline low-dose computed tomography (LDCT) was performed in those at high risk of lung cancer (PLCO(m2012) score ≥1.3% and/or meeting USPSTF 2013 criteria). RESULTS: Nearly one in five (19.7%) met criteria for undiagnosed COPD. Compared with those previously diagnosed, those undiagnosed were more likely to be male (59.1% versus 53.2%; p<0.001), currently smoking (54.9% versus 47.6%; p<0.001) and from an ethnic minority group (p<0.001). Undiagnosed COPD was associated with less forced expiratory volume in 1 s impairment (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 and 2: 85.3% versus 68.4%; p<0.001) and lower symptom/exacerbation burden (GOLD A and B groups: 95.6% versus 77.9%; p<0.001) than those with known COPD. Multivariate analysis demonstrated that airflow obstruction was an independent risk factor for lung cancer risk on baseline LDCT (adjusted OR 2.74, 95% CI 1.73–4.34; p<0.001), with a high risk seen in those with undiagnosed COPD (adjusted OR 2.79, 95% CI 1.67–4.64; p<0.001). CONCLUSIONS: Targeted case-finding within LCS detects high rates of undiagnosed symptomatic COPD in those most at risk. Individuals with undiagnosed COPD are at high risk for lung cancer. European Respiratory Society 2022-12-08 /pmc/articles/PMC10436757/ /pubmed/35896207 http://dx.doi.org/10.1183/13993003.00795-2022 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. |
spellingShingle | Original Research Articles Tisi, Sophie Dickson, Jennifer L. Horst, Carolyn Quaife, Samantha L. Hall, Helen Verghese, Priyam Gyertson, Kylie Bowyer, Vicky Levermore, Claire Mullin, Anne-Marie Teague, Jonathan Farrelly, Laura Nair, Arjun Devaraj, Anand Hackshaw, Allan Hurst, John R. Janes, Sam M. Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry |
title | Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry |
title_full | Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry |
title_fullStr | Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry |
title_full_unstemmed | Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry |
title_short | Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry |
title_sort | detection of copd in the summit study lung cancer screening cohort using symptoms and spirometry |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436757/ https://www.ncbi.nlm.nih.gov/pubmed/35896207 http://dx.doi.org/10.1183/13993003.00795-2022 |
work_keys_str_mv | AT tisisophie detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT dicksonjenniferl detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT horstcarolyn detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT quaifesamanthal detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT hallhelen detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT verghesepriyam detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT gyertsonkylie detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT bowyervicky detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT levermoreclaire detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT mullinannemarie detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT teaguejonathan detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT farrellylaura detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT nairarjun detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT devarajanand detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT hackshawallan detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT hurstjohnr detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry AT janessamm detectionofcopdinthesummitstudylungcancerscreeningcohortusingsymptomsandspirometry |